Management of Rash and Other Toxicities in Patients Treated with Epidermal Growth Factor Receptor—Targeted Agents

摘要: Inhibition of the epidermal growth factor receptor (EGFR) represents one most important avenues for research and development in field cancer therapy. The EGFR is a member ErbB tyrosine kinase (TK) family, which also includes ErbB-2 (HER2/neu), ErbB-3 (HER3), ErbB-4 (HER4). Current therapies available use include monoclonal antibodies, such as cetuximab, small-molecule TK inhibition by agents erlotinib. Side effects these dermatologic manifestations without bone marrow suppressive properties chemotherapy. Understanding rash how it relates to inhibitor toxicity and, perhaps more importantly, response must be clearly defined with clinical trials. optimum management patients receiving anti-EGFR therapy remains somewhat controversial; this secondary imprecise classification well lack trials determine appropriate treatment algorithm patients. We propose strategy help aggressively treat side allowing continue dose interruption or drug discontinuation.